A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)
ConditionActive Systemic Lupus Erythematosus
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorInventisBio Co., Ltd
About this trial
This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy and safety of D-2570 in the treatment of active systemic lupus erythematosus.
Eligibility criteria
Qualifiers
The patient voluntarily participates in this study after full informed consent.
The age is 18 years ≤ age ≤ 70 years, regardless of gender.
Diagnosed with Systemic Lupus Erythematosus (SLE) at least ≥ 24 weeks prior to screening.
SLEDAI-2K total score ≥ 8.
Disqualifiers
History of infection as defined in the protocol.
Any of the medical diseases or disorders listed in the protocol.
Significant, uncontrolled or unstable disease in any organ.
Trial design
Treatments tested in this trial
- D-2570
- D-2570 Placebo
Treatment groups
120 Participants
are divided into 4 treatment groupsLocations
1Map coordinates are unavailable for these locations. Locations are shown below instead.
Linfen Central HospitalRecruiting Linfen, Jiangxi
China
ChinaSponsors and collaborators
Source ClinicalTrials.gov